What is the difference between Mvasi and Avastin?

Amgen’s Mvasi (bevacizumab-awwb) is a biosimilar to Genentech’s Avastin (bevacizumab).

A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.

Both biologics are indicated for multiple types of cancer, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, brain cancer (glioblastoma), metastatic renal cell carcinoma (kidney cancer) and cervical cancers. Mvasi is not an interchangeable product with Avastin; the physician must write a prescription specifically for it.

See also:

https://www.drugs.com/history/mvasi.html

https://www.drugs.com/compare/avastin-vs-mvasi